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Abstract
Polycystic liver disease (PCLD) is an autosomal dominant disorder characterised by multiple fluid filled cysts in the liver. This
rare disease is caused by heterozygous germline mutations in PRKCSH and SEC63. We previously found that, in patients with
a PRKCSH mutation, over 76% of the cysts acquired a somatic ‘second-hit’ mutation in the wild type PRKCSH allele. We
hypothesise that somatic second-hit mutations are a general mechanism of cyst formation in PCLD which also plays a role in
PCLD patients carrying a SEC63 germline mutation. We collected cyst epithelial cells from 52 liver cysts from three different
SEC63 patients using laser microdissection. DNA samples were sequenced to identify loss of heterozygosity (LOH) mutations
and other somatic mutations in cyst epithelial DNA. We discovered somatic SEC63 mutations in patient 3 (1/14 cysts), but
not in patient 1 and 2 (38 cysts). Upon review we found that the germline mutation of patient 1 and 2 (SEC63
c.1703_1705delAAG) was present in the same frequency in DNA samples from healthy controls, suggesting that this variant
is not causative of PCLD. In conclusion, as somatic second-hit mutations also play a role in cyst formation in patients with
a SEC63 germline mutation, this appears to be a general mechanism of cyst formation in PCLD.
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Introduction
Polycystic liver disease (PCLD; MIM# 174050) is a rare,
dominantly inherited, disorder characterised by multiple fluid
filled cysts in the liver. The cysts, which develop from bile duct
epithelial cells (cholangiocytes), increase in size and number over
time and can lead to a massive increase in liver volume [1]. So far
two genes, PRKCSH (MIM# 177060) [2,3] and SEC63 (MIM#
608648) [4], have been associated with the development of PCLD.
A systematic sequencing effort demonstrated that PRKCSH
mutations account for 15% of the PCLD cases, whereas SEC63
mutations can be found in 6% [5].
In the case of a dominant disorder it is not always clear how
the heterozygous mutations can lead to disease and which
mechanisms are involved. The mutations can either lead to the
production of a mutated protein which disrupts the cell
function, or result in loss of functional gene product which
can lead to misregulation of dosage dependent genes. Often,
loss of a single allele will not have severe consequences for the
function of the cell and only after the remaining allele is lost
this will cause disease.
Recently, we demonstrated that in PCLD patients harbouring
a heterozygous PRKCSH mutation, over 76% of the cysts
acquired a somatic ‘second-hit’ mutation in PRKCSH [6]. These
mutations lead to total loss of functional PRKCSH in the cyst
epithelium suggesting that PCLD is recessive on a cellular level.
This finding is consistent with reports on other cystic diseases,
such as autosomal dominant polycystic kidney disease (ADPKD)
[7–12], where somatic second-hit mutations also are present in
cyst epithelia. We could also show that loss of the wild type
allele corresponded to loss of PRKCSH gene product hepato-
cystin in these cells [6,13]. Much less is known about how the
heterozygous mutations in SEC63 lead to cyst formation. On an
immunohistological level, cysts from PRKCSH and SEC63
patients show a different expression pattern for various proteins
including MUC1 and C-erbB-2. Furthermore, no loss of SEC63
protein has been reported in cysts form patients with a germline
mutation in this gene, which could reflect a different mechanism
of cyst development in cysts from SEC63 patients [14].
Although there is genetic and immunohistological heteroge-
neity among PCLD patients, the clinical presentation, the
presence of a normal bile duct system and the focal growth of
the cysts on the other hand, are features shared by all PCLD
patients [15]. This suggests that the mechanism of cyst
formation through second-hit mutations is similar among
different genetic forms of PCLD. We therefore hypothesise
that, similar to the situation in PRKCSH, somatic second-hit
mutations are also an important step in cyst formation in
patients with a SEC63 germline mutation.
To this end we analysed 52 cyst samples from 3 patients
carrying a SEC63 mutation. In one cyst sample we found loss of
heterozygosity (LOH), whereas we did not find any somatic
changes in 38 samples derived from the other two patients. After
reviewing the different germline mutations we found that somatic
inactivation only occurred against the background of the severe
truncating germline mutation.
These results show that somatic second-hit mutations play a role
in cyst formation of both PRKCSH and SEC63 mutation carriers.




Liver tissue and blood samples of patients were obtained and
stored in the course of treatment following the Dutch Code for the
proper secondary use of human tissue. Use of this tissue for
research was reviewed and approved by the regional ethics review
board ‘‘Commissie Mensgebonden Onderzoek (CMO) regio
Arnhem-Nijmegen’’.
DNA and Tissue Samples
We used the following strategy to obtain all known liver cyst
samples from SEC63 germline mutation carriers within the
Netherlands. Patients were selected based on sequencing results
from our molecular diagnostic laboratory, which routinely per-
forms diagnostic tests for PCLD. Each PCLD patient is tested for
PRKCSH as well as SEC63 and the database now holds 505
patients. Using this database we could readily identify 29 patients
with a SEC63 mutation. We cross checked these patients against
the Dutch National Pathology database to find those patients who
had undergone laparoscopic cyst fenestration because of severe
symptoms [16] and for whom cyst tissue samples would be
available. Following this strategy we identified 3 SEC63 germline
mutation carriers for whom blood and tissue samples were
available.
All patients were female, and age at the time of surgery varied
between 33 and 41 years-of-age. We used fresh tissue samples that
had been snap-frozen immediately after excision and stored at
280uC until analysis (n = 38; 2 patients), or formalin-fixed
paraffin-embedded liver tissue samples that had routinely been
collected for pathological examination (n= 14; 1 patient). All
samples were collected with appropriate ethics approval: written
informed consent for the use of secondary tissue was obtained from
all patients.
We collected whole blood from 1000 healthy controls (2000
chromosomes) which were recruited after advertisement in local
papers from the same geographical region as our patients.
Genotyping
We screened patient DNA from whole blood for germline
mutations in SEC63 and PRKCSH using direct sequencing as
described previously [6]. In brief, DNA from whole blood was
isolated using the PureGene DNA isolation kit (Gentra Systems,
Minneapolis, Minnesota, USA) and stored at 4uC. Exons and
flanking intronic sequences were amplified using polymerase chain
reaction (PCR) with specific primers. The amplified fragments
were purified (QIAEXII Gel Extraction Kit, Qiagen, Hilden,
Germany) and sequenced with the BigDye terminator kit and
ABI3730 capillary sequencer (Perkin Elmer Applied Biosystems,
Boston, MA, USA). Names of SEC63 mutations refer to the
NM_007214.4 transcript according to the HGVS guidelines.
We screened genomic DNA samples of 1000 healthy controls
for the SEC63 c.1703_1705delAAG mutation using PCR with the
forward primer 59-TAGTGAAATTGTCATCGAGTCAG-39
and the reverse primer 59-CGAGCAAGCAAACAAATGAA-39
followed by high resolution melting (HRM). Melting curves were
obtained from 65uC to 95uC with a ramp rate of 0.1uC/10
seconds in the CFX96TM Real-Time PCR Detection System
(Biorad Laboratories, Hercules, CA, USA) with EvaGreen
(Biotium, Hayward, CA, USA) as fluorescent dye. Melting curves
were analyzed using the Precision Melt software (Biorad).
Abnormal curves were then sent for sequencing.
Laser Microdissection
Tissue sections (10 mm), from frozen or formalin-fixed paraffin-
embedded liver samples, were mounted on cross-linked PEN-
membrane slides (Leica Microsystems GmbH, Wetzlar, Germany),
stained with Mayers Hematoxylin (1 min) and rinsed in tap water.
Paraffin embedded sections were deparaffinized using xylene and
ethanol prior to hematoxylin nuclear stain. Specific isolation of the
cyst epithelial cells (300 to 2000 cells/sample) was carried out
using a Leica Laser Microdissection system (LMD 6000) equipped
with an UV laser (Leica Microsystems GmbH) [17]. For each
patient we dissected liver cells (hepatocytes and other non-cyst
epithelial cells) to serve as a control sample.
DNA Isolation from Dissected Cells
DNA from the dissected cells was isolated using the QIAamp
DNAMicro kit (Qiagen) according to instructions and with the use
of carrier RNA. To increase the DNA yield and quality from
formalin fixed tissue samples we made the following adjustments:
samples were digested at 56uC for two days with occasional
agitation; proteinase K solution (.600 mAU/ml) was added in
two steps (5 ml on day 1 and 5 ml on day 2); after digestion and
addition of buffer ATL, samples were incubated at 90uC for 1 hr
to promote reverse cross-linking of the DNA. To obtain enough
material for the SEC63 and PRKCSH sequencing, cyst epithelial
DNA was amplified using a commercially available whole genome
amplification kit (GenomePlex WGA, Sigma-Aldrich, Saint Louis,
MO, USA) and purified (GenElute PCR Clean-Up Kit, Sigma-
Aldrich) prior to analysis. Sample amplification was performed in
duplicate to control for any mutations resulting from the whole
genome amplification procedure.
Somatic Mutation Analysis
We conducted the following analyses on DNA isolated from
laser dissected samples:
(1) SEC63 LOH analysis. The region of the germline mutation was
amplified using specific primers for the SEC63 c.958G.T
mutation (forward 59-TGAAAATTCCTGAGACCCTTG-39
and reverse 59-TGCTGCTTTCATCCCACTAA-39) and the
SEC63 c.1703_1705delAAG mutation (forward 59-TAGT-
GAAATTGTCATCGAGTCAG-39 and reverse 59-CGAG-
CAAGCAAACAAATGAA-39) followed by sequencing to
determine the heterozygosity state of the germline mutation
in both cyst epithelia and control liver cell samples.
(2) SEC63 and PRKCSH sequencing. All SEC63 and PRKCSH coding
exons and flanking intronic sequences were sequenced (as
described for genotyping) on amplified DNA to detect somatic
mutations in the cysts. DNA isolated from whole blood of the
patient was used as reference sample.
LOH Region Analysis
We used 5 heterozygous SNPs across chromosome 6 to analyse
the heterozygosity state in cyst DNA using PCR with specific
primers: rs2012025 (foward 59-GGGCCAGCAGAAA-
TAACTTG-39, reverse 59-GCTGTCGTTCTCATCATCCA-
39), rs13220047 (forward 59-TGTAGGTAAGGGAGATGCAC-
39, reverse 59-CCTACTGGACTCAGTGGTTT-39), rs675117
(forward 59-AGCCACAAGCTTTGGAATTG-39, reverse 59-
TTTAAATGCACTCACCAGAATTG-39), rs12210583 (forward
59-GCCTCAGAACCCTGAGCTG-39, reverse 59-AC-
CAAGGCTGTATCGCAATC-39) and rs10946279 (forward 59-
GCCGTGAGACAGCAAGTGT-39, reverse 59-
GGTTCCATCCCCAAGTCTCT-39), followed by sequencing.
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Immunohistochemistry
Tissue sections (4 mm) from formalin-fixed paraffin-embedded
PCLD liver tissue were obtained together with tissue sections for
laser micro dissection. Sections were mounted on SuperFrost
Plus glass slides (Thermo Scientific Waltham, MA, USA) using
a water bath and allowed to dry overnight at 37uC. Prior to the
staining the tissue sections were deparaffinised with xylene and
hydrated with alcohol and distilled water. Samples were
microwave heated and boiled for 10 min in Na-Citrate buffer
pH 6, cooled down to room temperature, washed in phosphate
buffered saline (PBS) and incubated for 30 min with 1%BSA/
PBS (Bovine Serum Albumin, Sigma-Aldrich). Endogenous
Avidin/Biotin was blocked (Vector laboratories, Burlingame,
CA, USA) followed by overnight incubation with 1:400 rabit
anti-SEC63 antibody (kind gift from Prof. Dr. Enno Hartmann,
University of Lu¨beck, Germany), 1:200 mouse anti-hepatocystin
antibody (sc10774, Santa Cruz, CA, USA) or 1:400 mouse anti-
Cytokeratin 19 (MU246-UC, BioGenex, San Ramon, CA) in
1%BSA/PBS. For each staining we included a negative control
in which the primary antibody was omitted. Endogenous
peroxidase was blocked in 0,3% H2O2/PBS for 10 min after
which samples were washed in PBS. Samples were incubated
for 1 hr with secondary antibody (biotinylated anti-mouse or
anti-rabit IgG, Vector laboratories), washed and bound to
Horse-Radish-Peroxidase using the ABC method (Vector
laboratories). Detection was carried out with the use of
diaminobenzidine tetrahydrochloride (DAB) as substrate and
enhanced with copper sulfate and nuclei were counterstained
with Mayers Hematoxylin. After the staining samples were
dehydrated with alcohol and xylol before mounting in
Permount.
Statistics
Fisher’s exact test was used to compare the frequency of the
SEC63 c.1703_1705delAAG variant in DNA samples from PCLD
patients with healthy controls, and to compare the presence of
LOH and somatic point mutations in cyst between patients with
a PRKCSH or a SEC63 germline mutation. The 95% confidence
interval of the proportion of cysts with LOH was calculated with




We obtained tissue samples from three patients with a known
SEC63 germline mutation (Table 1), these 3 patients are unrelated
and no affected family members are known. We also screened
genomic DNA for mutations in PRKCSH, the other gene involved
in PCLD, to exclude additional germline mutations.
Somatic Mutation Analysis
Using laser microdissection we collected epithelial cells from 52
cysts and found LOH to be present in one cyst from patient #3
(Table 1, Figure 1B). Next, we screened the coding sequence of
SEC63 and PRKCSH by Sanger sequencing in the remaining cysts
of patient#1 and patient #2, no somatic mutations were present.
Due to the formalin fixation in the samples of patient #3 we could
not sequence SEC63 and PRKCSH to detect other somatic
mutations in these samples.
LOH Region Analysis
We used 5 informative (heterozygous) single nucleotide poly-
morphisms (SNPs) across chromosome 6 to determine the extent
of the region with LOH (Figure 1A, B and C). This demonstrated
that the LOH region extends over 6 kb from the site of the
germline mutation SEC63 c.958G.T (in exon10) to exon 6 in the
same gene. The SNP (rs13220047) located at a distance of 82 kb
remains heterozygous indicating that a genomic breakpoint
occurred within this region. In tumour samples LOH regions
are often telomeric [19,20] and extent from one breakpoint
towards the end of the chromosome. This was not the case in our
sample, where the telomeric SNPs remained heterozygous
(Figure 1C).
Immunohistochemistry
Immunostaining of SEC63 and hepatocystin showed that the
hepatocystin staining was similar between cysts, whereas for
SEC63 the intensity of the staining was reduced in the cyst with
LOH but appears normal in the cysts without loss of heterozy-
gosity (Figure 1D).
Somatic Mutations Only Present in Patient with Severe
Germline Mutation
We found LOH in one of the 14 cysts of patient #3, while
somatic mutations were conspicuously absent from samples from
the other 2 patients (38 cysts). We reviewed the different
underlying SEC63 germline mutations and found that the germline
mutation of patient #3 is potentially much more severe than those
of the other 2 patients. Both patient #1 and #2 carry
a heterozygous SEC63 c.1703_1705delAAG mutation which will
lead to an in-frame deletion of a single amino acid: glutamate at
position 568 in the protein. In contrast, the germline mutation of
patient #3 (SEC63 c.958G.T) results in a premature stop codon
after 319 amino acids (p.Glu320X), which deletes 441 out of 760
amino acids.
To determine whether the SEC63 c.1703_1705delAAG muta-
tion is a true pathogenic mutation or represents a rare (benign)
polymorphism, we determined the frequency of this mutation in
the normal population by high resolution melting analysis of this
region in genomic DNA of 1000 healthy subjects. We found this
specific amino acid deletion in 6 out of 2000 normal chromosomes
Table 1. Somatic mutation analysis.





Patient 1 38 F Frozen SEC63 c. 1703_1705delAAG 34 0 (0%)
Patient 2 41 F Frozen SEC63 c. 1703_1705delAAG 4 0 (0%)
Patient 3 33 F Formalin fixed SEC63 c. 958G.T 14 1 (7%)
*Age at time of surgery.
doi:10.1371/journal.pone.0050324.t001
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(0,30%), which is similar to the frequency present in a sample of
373 PCLD patients (5/746 chromosomes, 0,67%) as depicted in
Figure 2. The difference between both groups was not statistical
different (p = 0.18). This suggest that the genomic variant SEC63
c.1703_1705delAAG is not a pathogenic mutation causing PCLD
which may explain the absence of any somatic mutations in this
gene.
Discussion
Our data show that somatic second-hit mutations do occur in
SEC63 mutation carriers with PCLD, which is in line with the
second-hit model for disease pathogenesis.
We did not detect somatic mutations in two out of three patients
and we hypothesised this was related to the nature of the germline
mutation. After reviewing the germline mutations we found that
Figure 1. Cyst with loss of heterozygosity. Electropherograms showing the heterozygous germline mutation SEC63 c.958G.T and two
neighbouring SNPs in control liver tissue (A) and in the homozygous liver cyst (B) of patient 3, indicating loss of heterozygosity at SEC63 c.958G.T
and SNP rs675117 in the cyst. The relative locations of the different SNPs are shown, with a close up of the genomic region surrounding the germline
mutation (C). The SNPs which remain heterozygous in the cyst with LOH are depicted in blue, SNPs with LOH are depicted in red on the chromosome
(C). Immunohistochemical analysis shows the expression of SEC63 and hepatocystin in a normal bile duct, a heterozygous liver cysts and the
homozygous liver cyst with LOH at SEC63, in a paraffin-embedded formalin-fixed tissue section of patient #3 (D).
doi:10.1371/journal.pone.0050324.g001
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the allele frequency of the SEC63 c.1703_1705delAAG mutation
did not differ between our PCLD patients and the healthy
population. This indicates this variant is a (rare) polymorphism
which is not associated with PCLD. The literature reports this
mutation several times in relation to PCLD [4,5] but segregation
in a family with PCLD has never been shown. Davila et al.
reported that they did not find this variant in 360 healthy
chromosomes [4], which can be explained by the low allele
frequency of this variant. We therefore believe that patients 1 and
2 do not have a pathogenic SEC63 mutation, but belong to the
cohort of PCLD patients in which the genetic cause is still
unknown. This is important to know as currently patients with
PCLD are being screened, classified and advised based on wrong
information.
As PRKCSH and SEC63 are ubiquitously expressed in the
human body, it remains unclear why germline mutations would
lead to a liver specific disorder. The gene product of SEC63,
SEC63, is thought to play a role in protein transport across the
endoplasmic reticulum (ER) membrane, whereas PRKCSH codes
for hepatocystin and is part of a heterodimer complex involved in
folding of glycoproteins in the ER [21,22]. However, targeted
inactivation of both PRKCSH and SEC63 in an ADPKD mouse
model leads to a synergistic increase in disease severity, which
suggests that these genes share a biological pathway [23].
Although the frequency of somatic second-hit mutations varies
between different genes and genetic disorders, the difference in
somatic mutations between cysts from PRKCSH patients and this
SEC63 patient is remarkable. We found LOH in only 7% (1/14) of
SEC63 mutated cysts, whereas in PRKCSH germline carriers the
majority of cysts (76%) acquired LOH [6]. Although the numbers
are low, this difference is statistically significant (p,0,00001) and
could indicate that these two genes have a different susceptibility to
somatic LOH. The immunohistochemical data confirmed loss of
SEC63 protein in the cysts with LOH, which indicates that the
truncated gene transcript from the mutated SEC63 c.958G.T
allele may no longer be translated into protein or is not recognised
by the antibody.
Our study was restricted by the limited amount of available
patient tissue. However, we identified and collected all known
PCLD liver tissue samples that had been stored within the
Netherlands. We obtained samples from three patients, but only
one patient carried a bonafide pathogenic SEC63 germline
mutation. Furthermore, the available tissue was formalin fixed
which was not a problem for the laser microdissection
procedure, but did reduce the yield of the DNA isolation. We
were able to get a clear read on the LOH status of all samples,
but the sequence efficiency was affected in material derived
from formalin-fixed paraffin-embedded tissue. Therefore there
may still be presence of, yet unidentified, somatic mutations in
these samples.
There is a body of evidence emanating from recent studies
supporting the concept of somatic mutations as part of the
genetic pathogenesis of benign and malignant disorders. It was
recently shown that hamartomata that are part of the Proteus
syndrome arise from somatic activating mutations in oncogene
AKT1 [24]. In patients with acute lymphoblastic leukemia and
cervical cancer somatic mutations play an important role in the
development and prognosis of the disease [25,26]. Lastly,
recurrent somatically acquired mutations of the SF3B1 gene
can be demonstrated in subtypes of myelodysplastic syndromes
in which ring sideroblasts are a prominent feature [27].
Collectively, these data demonstrate that genetic inactivation
through somatically acquired mutations help to understand the
tissue specificity of certain malignant but also non-malignant
disorders.
In conclusion, we have now shown that in both PRKCSH and
SEC63 somatic second-hit mutations can occur which supports the
notion that somatic second-hit mutations are part of the genetic
mechanism in cyst formation in PCLD.
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